Cantor Fitzgerald Initiates Coverage On Lexicon Pharmaceuticals with Overweight Rating, Announces Price Target of $8

Cantor Fitzgerald analyst Steve Seedhouse has initiated coverage on Lexicon Pharmaceuticals (NASDAQ: LXRX) with an Overweight rating. The firm has set a price target of $8 for the company's stock.